IN THE CLAIMS

1. - 57. (Canceled)

58. (Currently amended) A crystalline form ~~according to claim 1~~ wherein said form is form J.

59. (Original) A crystalline form according to claim 58 wherein said form is characterized as containing 2-5% water and 1-5% n-propanol by weight in a powder sample.

60. (Original) A crystalline form according to claim 58 wherein said form is further characterized as having a 13C solid state NMR spectrum comprising a plurality of peaks with chemical shifts of about 179.6 ppm, 178.4 ppm, 25.2 ppm, 11.5 ppm, 10.0 ppm, 9.3 ppm, 8.1 ppm and 6.8 ppm.

61. (Original) A pharmaceutical composition comprising a crystalline form of azithromycin according to claim 58 and a pharmaceutically acceptable excipient.

62. - 108. (Canceled)

109. (Original) A method of preparing the crystalline form of claim 58 comprising the steps of dissolving azithromycin in n-propanol, adding water, precipitating azithromycin crystals and isolating the crystals.

110. - 122. (Canceled)

123. (Currently amended) A method of treating a bacterial infection or a protozoa infection in a mammal, fish, or bird which comprises administering to said mammal, fish or bird a therapeutically effective amount of crystalline azithromycin ~~according to claim 1 or an azithromycin mixture according to claim 86~~ form J.